Exelixis Soars 28.81% on Stellar-303 Trial Success

On June 23, 2025, Exelixis shares surged by 28.81% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Exelixis recently announced positive results from its phase 3 Stellar-303 trial, which demonstrated a statistically significant overall survival benefit for patients treated with a combination of zanzalintinib and atezolizumab. This breakthrough has been widely recognized as a major advancement in the treatment of metastatic colorectal cancer, as it showed a significant reduction in the risk of death compared to regorafenib.

The positive outcomes from the Stellar-303 trial have been a key driver behind the recent surge in Exelixis' stock price. The combination therapy not only improved overall survival but also did not reveal any new safety signals, further bolstering investor confidence in the company's innovative approach to cancer treatment.

Exelixis' success in this pivotal trial underscores the company's commitment to developing groundbreaking therapies that can improve patient outcomes. The positive results have positioned Exelixis as a leader in the oncology space, with investors eagerly anticipating further developments and potential approvals for this combination therapy.